In May 2026, the FDA granted De Novo approval to a device called the Modius Spero, built by a Belfast-based company named Neurovalens. It is the first neuromodulation device ever approved for PTSD. Starting this summer, the VA is making it available to veterans.
That is worth sitting with for a moment. No new medication has been approved for PTSD in the United States since 2001. For twenty-five years, the treatment toolbox has stayed largely the same: a handful of medications, various forms of talk therapy, and combinations of the two. This is the first new FDA-approved option of any kind in a generation, and it is not a pill.
What it is
The Modius Spero is a small wearable device. It does not require surgery. It does not involve any drugs.
It is prescribed by a clinician, and use is supervised as part of a treatment plan. It is meant to work alongside existing PTSD care, not instead of it.
The device is worn during a 30-minute session, once a day, at home. There is no clinic visit required for each session. The clinician's role is to prescribe it, set expectations, and check in on progress — not to administer every use.
How it works
The Modius Spero uses something called electrical vestibular system stimulation, or VSS. In plain terms: it sends low-level electrical pulses through electrodes placed behind the ear. Those pulses target the vestibular nerve — the nerve system tied to balance and spatial orientation — which also connects to brain regions involved in mood and stress regulation.
There is no cutting, no implant, and no medication absorbed into the bloodstream. The device sits behind the ear like a small headset attachment, and the person wearing it goes about a quiet 30 minutes at home — often reading, resting, or doing something low-key while the session runs.
The idea behind targeting the vestibular nerve is that it is not an isolated system. It has established connections to parts of the brain involved in regulating stress responses and emotional state, which is the basis for why stimulating it may have effects that reach beyond balance and orientation.
Neurovalens is not new to this approach. The company already has FDA-approved devices for insomnia (Modius Sleep) and anxiety (Modius Calm), both of which are already available to veterans through the VA. The Modius Spero is the same underlying technology, applied to PTSD.
What the trial showed
The FDA's approval was based on a clinical trial of 383 adults across the United States, all with a PTSD diagnosis. The trial ran for 12 weeks.
About two-thirds of participants — roughly 67 percent — saw clinically meaningful improvement in their PTSD symptoms.
Twelve weeks is a defined, relatively short window, and a controlled trial is not the same as everyday life. But it is the standard the FDA uses to evaluate whether a device does what it claims, and this trial met that bar.
That is not a cure rate, and Neurovalens has not claimed it is one. It is a meaningful clinical result for a condition where treatment options have been narrow for a long time. It is also the number the FDA reviewed before granting approval — not a marketing claim layered on afterward.
Who can get it now
Right now, access runs through the VA, and veterans are first in line. The device is approved for adults age 22 and older.
Wider access — meaning broader insurance reimbursement and prescription availability outside the VA system — is expected sometime in 2027. For now, if you are not a veteran, this is not yet something you can walk into a clinic and get prescribed.
If you are a veteran, the path is straightforward: it is a clinician-prescribed and supervised device, so it starts with a conversation with a provider inside the VA system.
This also is not the first time the VA has been the entry point for Neurovalens technology. Modius Sleep, for insomnia, and Modius Calm, for anxiety, both went through the VA before reaching a wider market. The Modius Spero appears to be following the same rollout pattern.
What it means
New treatment categories for PTSD do not appear often. When they do, it is worth being precise about what changed and what did not.
What changed: there is now an FDA-approved wearable device that does not rely on medication, and a real trial showing a majority of participants got meaningfully better. That is new, and it is significant.
What did not change: the Modius Spero is designed to complement existing treatment — not replace therapy, medication, or other established care. It is not a stand-alone fix, and nobody involved in its approval has claimed otherwise.
For veterans specifically, this also means the VA is once again the first place a new mental health technology becomes available. Given that PTSD affects veterans at meaningfully higher rates than the general population, being first in line for a new, non-drug option is not a small thing.
It is also worth being clear about the limits of what is known. The device is approved for adults 22 and older, and access outside the VA is not yet in place. Anyone considering it should treat this as one option to discuss with a provider — not a replacement for a broader conversation about care.
Veterans deserve access to every honest conversation about what is actually working in mental health treatment — not just the ones with the best marketing. Lumafy is not a clinical tool, and it does not treat PTSD or any other condition. It is built for the part of recovery that happens between appointments: the daily check-ins, the patterns that show up over weeks, the hard days, and the ones that feel a little better. That is a different job than a device like the Modius Spero is doing, and it is one worth doing well.
Lumafy AI is built by Summa Studios out of Nappanee, Indiana. Hero Mode and Recovery Mode are always free. If you are in crisis, call or text 988 and press 1 for the Veterans Crisis Line.